Several algorithms help physicians base appropriate therapy on signs and symptons
ESCRS 2024: Approaching a paradigm shift in cell therapy for corneal oedema and endothelial dysfunction
Michael Goldstein, MD, discusses 12-month safety and efficacy trial data of human corneal endothelial cell therapy, presented at the 2024 ESCRS Congress
Magnetic cell therapy for corneal endothelial dysfunction
Phase 1 multicentre study data demonstrate early signs of efficacy
European Commission grants marketing authorization for treatment of acanthamoeba keratitis
Akantior, an anti-amoebic polymer eye drop, is the first and only authorised medical product for the treatment of AK in the world, according to a news release.
The shifting landscape of conjunctival hyperemia
European patients navigate new therapies and market change-ups
Research indicates long-term effect of COVID-19 on corneal endothelial cell morphology
Specular microscopy showed "long-term alterations" in corneal cells
Novaliq receives positive CHMP opinion for Vevizye in treatment of dry eye disease
The positive opinion comes with the recommendation that ciclosporin 0.1% be granted marketing authorisation in the European Union
